← Back to all trials
Recruiting
NCT05601388
Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study
Conditions: Colorectal Cancer
Sex: All
Enrollment: 60
Sponsor: Sohag University
Location: Egypt
Summary
Colorectal carcinoma (CRC) is the third most common malignancy worldwide.
In Egypt, the relative frequency of CRC is about 9-12% with high male predominance 3:1.
The high mortality rates associated with CRC is reflective of several factors including: the lack of apparent symptoms in the early stages and the absence of cancer prevention strategies in developing countries.Insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a member of the IMP family which plays a key role in the transfer and stabilization of mRNA, cell growth, and migration during embryogenesis.
IMP3 has gained considerable interest as a cancer-associated protein.
Previous studies strongly suggest that IMP3 may represent a valuable prognostic marker in human cancer.
Its overexpression has been reported in a variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer, gastric cancer, liver cancer, and breast cancer
Eligibility Criteria
Inclusion Criteria:Patients with CRC and will be underwent surgery.Exclusion Criteria:- Patients received pre-operative chemotherapy or radiotherapy.Patients with insufficient clinical data.
Source: ClinicalTrials.gov (NCT05601388). StuddyBuddy aggregates publicly available trial information.